QBIO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 apr 2024 @ 20:32):

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies...

Stats
Dagens volum	1 123.00
Gjennomsnittsvolum	23 222.00
Markedsverdi	29 019.00
EPS	$0 ( 2024-03-13 )
Neste inntjeningsdato	( $0 ) 2024-05-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-05-26	Corin Denis	Buy	200 000	Common Stock
2021-02-01	Rosenstadt William S	Buy	35 000	Common stock
2020-10-27	Corin Denis	Buy	500 000	Incentive Stock Options
2020-08-29	Corin Denis	Buy	150 000	Incentive Stock Options
2020-08-29	Corin Denis	Buy	150 000	Incentive Stock Options

INSIDER POWER
100.00
Last 100 transactions
Buy: 7 488 702 \| Sell: 150 251

Q BioMed Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Q BioMed Inc. Økonomi

Annual	2022
Omsetning:	$284 352
Bruttogevinst:	$-8 988.00 (-3.16 %)
EPS:	$-0.0160

FY	2022
Omsetning:	$284 352
Bruttogevinst:	$-8 988.00 (-3.16 %)
EPS:	$-0.0160

FY	2021
Omsetning:	$195 597
Bruttogevinst:	$-51 249.00 (-26.20 %)
EPS:	$-0.298

FY	2020
Omsetning:	$30 000.00
Bruttogevinst:	$-296 009 (-986.70 %)
EPS:	$-0.650

Financial Reports:

No articles found.

Q BioMed Inc.

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.